Grifols’ $4 billion buyout of RTP-based Talecris a year ago is paying big dividends for the Spain-based international provider of blood plasma products.

Grifols, which maintains Talecris operations taken over in the deal that closed last June in RTP and Johnston County, reported profits of $87 million on sales of more than $800 million, Bloomberg news and Reuters reported.

Analysts at Bloomberg had forecast 10 percent lower sales and earnings of some $67 million.

Sales were up 17 percent.

“Topline is already benefiting from synergies in revenues and underlying profitability is progressing much faster than the slight sequential improvement that we were anticipating,” analyst Bryan Garnier said in a note to clients, according to Reuters.